Global funding for hepatitis C virus (HCV) testing is insufficient, with significant diagnostic challenges arising from access, particularly among at-risk populations such as drug users and the incarcerated. Innovative approaches like decentralized testing and community-based models are being adopted to bridge these gaps, allowing for immediate diagnosis and treatment. Recent declines in funding have hindered efforts to eliminate HCV, despite the introduction of effective diagnostic tools. Collaboration among public and private sectors is deemed crucial for achieving HCV elimination by 2030.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.